Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1997 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Michael Berkel who wrote (8459)	12/16/1997 1:38:00 PM
From: NYBellBoy	Read Replies (3) \| Respond to of 9285

Michael B.- -shorted Zona yesterday 20 3/8 now @ 23 1;43pm est. Timing in life is everything and most of the time my timing stinks. :0 BellBoy

To: Michael Berkel who wrote (8459)	12/16/1997 3:45:00 PM
From: Roger A. Babb	Respond to of 9285

Michael, I am not currently short ZONA.

To: Michael Berkel who wrote (8459)	12/16/1997 9:28:00 PM
From: Bill Wexler	Read Replies (1) \| Respond to of 9285

RE: ZONA...Some research on oral phentolamine... "Experience with buccal phentolamine mesylate for impotence," Zorgniotti, A.W., Dept. Of Urology, New York University School of Medicine, NY 10016, Int J Impotence Res., 1994 Mar, 6:1, 37-41. Zonagen has nothing new or exciting. The effectiveness of oral or sub-lingual phentolamine for the treatment of ED is seriously in doubt. Zonagen has obfuscated the results of Phase II and II trials and has played fast and loose with defining the endpoints. Phentolamine is a generic drug which is readily available from multiple sources. Zonagen's "method-of-use" patent claims are laughable and absurd. Zonagen is a scam.